BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31597506)

  • 1. Two novel TSC2 mutations in renal epithelioid angiomyolipoma sensitive to everolimus.
    Wang T; Xie S; Luo R; Shi L; Bai P; Wang X; Wan R; Deng J; Wu Z; Li W; Xiao W; Wang Y; Chen B; Zhang K; Xing J
    Cancer Biol Ther; 2020; 21(1):4-11. PubMed ID: 31597506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.
    Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G
    Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal angiomyolipoma (AML) harboring a missense mutation of
    Idogawa M; Hida T; Tanaka T; Ohira N; Tange S; Sasaki Y; Uhara H; Masumori N; Tokino T; Natori H
    Cancer Biol Ther; 2020 Apr; 21(4):315-319. PubMed ID: 31847710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
    Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
    Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density.
    Hatano T; Atsuta M; Inaba H; Endo K; Egawa S
    Int J Clin Oncol; 2018 Jun; 23(3):547-552. PubMed ID: 29256023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.
    Giannikou K; Malinowska IA; Pugh TJ; Yan R; Tseng YY; Oh C; Kim J; Tyburczy ME; Chekaluk Y; Liu Y; Alesi N; Finlay GA; Wu CL; Signoretti S; Meyerson M; Getz G; Boehm JS; Henske EP; Kwiatkowski DJ
    PLoS Genet; 2016 Aug; 12(8):e1006242. PubMed ID: 27494029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
    Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
    Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
    Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
    Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.
    Hatano T; Inaba H; Endo K; Egawa S
    Int J Urol; 2017 Nov; 24(11):780-785. PubMed ID: 28905429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
    Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
    BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.
    Lattanzi M; Deng FM; Chiriboga LA; Femia AN; Meehan SA; Iyer G; Voss MH; Sundatova Y; Huang WC; Balar AV
    J Immunother Cancer; 2018 Oct; 6(1):97. PubMed ID: 30285856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma.
    Shitara K; Yatabe Y; Mizota A; Sano T; Nimura Y; Muro K
    Jpn J Clin Oncol; 2011 Jun; 41(6):814-6. PubMed ID: 21415002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
    Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
    Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
    PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan.
    Hatano T; Chikaraishi K; Inaba H; Endo K; Egawa S
    Int J Urol; 2016 Oct; 23(10):833-838. PubMed ID: 27480662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.
    Tsai JD; Wei CC; Yang SH; Fan HC; Hsu CC; Tung MC; Tsai ML; Sheu JN
    Nephrology (Carlton); 2017 Dec; 22(12):1017-1022. PubMed ID: 27565896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-phenotype correlation of patients with tuberous sclerosis complex-associated renal angiomyolipoma: a descriptive study.
    Li S; Zhang Y; Wang Z; Yang Y; Gao W; Li D; Wei J
    Hum Pathol; 2018 Dec; 82():61-67. PubMed ID: 30036593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.